Close Menu

NEW YORK — Evogen's Cognizance Biomarkers subsidiary has launched a clinical trial with Mayo Clinic to validate its proteomic test for distinguishing between epileptic seizures and psychogenic non-epileptic seizures (PNES).

The company has received IRB approval from Mayo and plans to begin enrolling patients within the next several weeks, said Todd Wallach, president and CEO of Cognizance. He said that the trial aims to enroll 216 patients over the next year, with the primary goal of the study being to finalize the test's protein marker panel and algorithm.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.